ONCOtracker, Inc

ONCOtracker, Inc is a pioneering incubator in the field of cancer treatment innovation, with a key focus on the diagnosis and treatment of multiple myeloma. Founded by myeloma research pioneer and oncologist, James R. Berenson, M.D., the company offers a range of proprietary services including serum BCMA testing, patient-derived xenografts (PDX), access to a vast library of clinically characterized biospecimens, and consultative services. Based in West Hollywood, CA and founded in 2014, ONCOtracker's facilities, featuring a state-of-the-art GLP laboratory and biorepository, are optimally equipped to support drug development and clinical studies around the globe. The company has played a critical role in providing testing, biospecimens, patient-derived xenografts, and consultative guidance to various research institutions, pharmaceutical companies, and contract research organizations worldwide to advance the development of BCMA-directed drugs. ONCOtracker is open to discussing how its unique testing services and programs can contribute to specific drug development needs in the Biopharma and Pharmaceutical industries.